Greenphire Empowers Orphan Drug and Rare Disease Clinical Research
Anthera Pharmaceuticals to leverage Greenphire’s ClinCard with Travel Module to improve site satisfaction, patient retention and engagement
King of Prussia, PA – April 19, 2016 – Greenphire, the global leader in clinical payment solutions, today announced that its ClinCard Travel Module solution continues to empower clinical research in the orphan drug and rare disease market. With this announcement, Greenphire has expanded its client partners to include Anthera Pharmaceuticals, a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.
The Orphan Drug Act of 1983 (ODA) has driven an increase in research and drug approvals for rare diseases over the last five years. In fact, 17 of the 39 drug approvals granted by FDA in 2013 were for orphan drugs exclusively. The ClinCard Travel Module solution has been embraced by the orphan drug and rare disease community because of its ability to be configured specifically to meet the complex and sensitive needs of this research.
Anthera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including the first non-porcine exocrine pancreatic insufficiency treatment, Systemic Lupus Erythmatosus (SLE), and IgA nephropathy. The Company is using the ClinCard Travel Module solution to simplify patient reimbursement and eliminate any financial hurdles that may impact patient engagement and retention.
“Our research in patients with Cystic Fibrosis, Lupus and IgA nephropathy trials can impact not only the patients, but their families and caregivers. The ClinCard with Travel Module is a powerful solution designed to meet the unique needs of our research, taking the burden of reimbursements and travel arrangements out of the hands of the research sites and eliminating any out-of-pocket costs for our patients and families,” said Monica Gangal, Senior Director of Clinical Operations for Anthera Pharmaceuticals. “Collaborating with Greenphire to bring this solution to our research further illustrates our ongoing commitment to providing a superior trial experience that is focused on top quality care.”
The ClinCard Travel Module allows participants to travel for the study without incurring out-of-pocket costs and ensures travel arrangements are aligned with sponsor travel policies and approval requirements.
“Patient retention and engagement is critical to the success of clinical research, and no one knows this more than orphan drug and rare disease organizations. By eliminating financial burdens for patients and their families, including travel and lodging arrangements, our solutions reduce drop out and support a better trial experience for patients, their families and the research sites they work with,” said Jim Murphy, CEO of Greenphire. “We’re excited that Anthera has joined our growing list of client partners in this community and we are committed to ensuring the success of its innovative research.”
Greenphire will be showcasing its clinical trial payment solutions, including the ClinCard Travel Module, at the World Orphan Drug Congress taking place in Washington D.C. from April 20-22.
Greenphire is the leader in global clinical trial payment solutions. Greenphire’s best-in-class solutions optimize clinical trial performance by simplifying and streamlining payment processes from sponsors and CROs to sites and patients. Greenphire’s ClinCard and eClinicalGPS solutions easily handle any type of trial design and complexity, resulting in more accurate and compliant payments globally for both sites and patients. The choice of industry leaders worldwide, Greenphire provides better performance and better data, resulting in better trials. Learn more atwww.greenphire.com.